Natural Killer (NK) Cell Immunotherapy Towards Adult T Cell Leukemia (ATL) via Exaltation of MICA/B Expression and Augments NK Cytotoxicity
Natural Killer (NK) Cell Immunotherapy Towards Adult T Cell Leukemia (ATL) via Exaltation of MICA/B Expression and Augments NK Cytotoxicity
批准号:
22K16327
负责人:
Panaampon Jutatip
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Early-Career Scientists
财政年份:
2022
资助国家:
日本
项目状态:
已结题
起止时间:
2022-04-01 至 2024-03-31
中文摘要
我们检查了各种ATL细胞系(艾德-、TL-Om 1、S1 T、KK-1、LMHW 5、OATL-4和SU 9 T1)上的云母/B表达。我们发现艾德-和TL-Om 1在细胞表面上高云母/B,而S1 T细胞显示非常低/无云母/B表达。我们使用艾德-、TL-Om 1作为代表性云母/Bhigh ATL,使用S1 T作为云母/Bno ATL。然后,我们测试了S1 T、艾德-和TL-Om 1的NK细胞毒性,发现具有非常低的云母/B表达的S1 T细胞抵抗NK细胞毒性,而艾德-和TL-Om 1对NK细胞毒性敏感。结果表明,云母/B,这是NKG 2D配体是至关重要的NK细胞的细胞毒性。我们证明iMID增加ATL上的云母/B表达。我们测试了iMID治疗对云母/B表达的功效。在本研究中检测了来那度胺、泊马度胺、伊贝度胺、CC-92480。用ATL测试非细胞毒性剂量。在所有这些中,CC-92480显示最高的增强云母/B表达的功效。通过使用来自健康供体的原代NK细胞,我们发现来那度胺、泊马度胺、伊贝度胺和CC-92480使ATL对NK细胞毒性敏感,并且CC-92480在iMID中显示最高功效。
英文摘要
We checked MICA/B expression on various ATL cell lines (ED-, TL-Om1, S1T, KK-1, LMHW5, OATL-4, and SU9T1). We found ED- and TL-Om1 express high MICA/B on cell surface whereas S1T cell shows very low/no MICA/B expression. We used ED-, TL-Om1 as representative MICA/Bhigh ATL and S1T as MICA/Bno ATL. We then test S1T, ED-, and TL-Om1 for NK cytotoxicity and found that S1T cells which have very low MICA/B expression, resist to NK cell cytotoxicity whereas ED-, and TL-Om1 are sensitive to NK cytotoxicity. The results suggest that MICA/B, which is NKG2D ligand is crucial for NK cell cytotoxicity.We demonstrate iMIDs increase MICA/B expression on ATL. We tested the efficacy of iMIDs treatment for MICA/B expression. Lenalidomide, Pomalidomide, Iberdomide, CC-92480 were tested in this study. The noncytotoxic doses were tested with ATL. Among all of those, CC-92480 show highest efficacy to enhance MICA/B expression. By using primary NK cells from healthy donor, we found that Lenalidomide, Pomalidomide, Iberdomide and CC-92480 sensitized ATL to NK cytotoxicity and CC-92480 displayed the highest efficacy among iMIDs.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
TKM-011, Anti-CD20 Antibody Confers Multi-Properties Against Burkitt’s Lymphoma in Comparable Efficacy to Rituximab and Obinutuzumab
TKM-011,抗 CD20 抗体具有对抗伯基特淋巴瘤的多种特性,其疗效与利妥昔单抗和 Obinutuzumab 相当
DOI:
--
发表时间:
2022
期刊:
影响因子:
--
作者:
[池田翔, 阿部滉, 北館明宏, 田川博之, 髙橋直人, Jutatip Panaampon and Seiji Okada]
通讯作者:
Jutatip Panaampon and Seiji Okada
DOI:
10.21873/anticanres.16259
发表时间:
2023-02
期刊:
AntiCancer Research
影响因子:
2
作者:
[Ployploen Phikulsod;R. Kariya;Jutatip Panaampon;S. Okada]
通讯作者:
Ployploen Phikulsod;R. Kariya;Jutatip Panaampon;S. Okada
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells
Elotuzumab 是一种潜在的治疗性人源化抗 SLAMF7 单克隆抗体,可增强自然杀伤细胞介导的原发性渗出性淋巴瘤细胞杀伤作用
DOI:
10.1007/s00262-022-03177-6
发表时间:
2022
期刊:
Cancer Immunology, Immunotherapy
影响因子:
--
作者:
[Panaampon Jutatip, Kariya Ryusho, Okada Seiji]
通讯作者:
Okada Seiji
海外基金